Claret Capital, a company that provides financing to growth-stage European companies with strong management and proven revenue traction in substantial markets, and Kreos, a provider of innovative and flexible debt solutions, completed the $150m investment in Abivax, a French clinical-stage, publicly traded biotechnology company. “We’re delighted to have advised on the investment into Abivax, alongside the Kreos team. With the impressive long-term safety and efficacy seen in Phase IIa and Phase IIb trials, the Fund’s investment reflects our belief that Obefazimod can have a significant positive impact on the lives of patients,“ David Bateman, Claret Capital Managing Partner.